126 related articles for article (PubMed ID: 2066987)
1. 2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors.
Knebel NG; von Angerer E
J Med Chem; 1991 Jul; 34(7):2145-52. PubMed ID: 2066987
[TBL] [Abstract][Full Text] [Related]
2. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
von Angerer E; Birnböck H; Knebel N
Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
[TBL] [Abstract][Full Text] [Related]
3. Carrier mediated action of platinum complexes on estrogen receptor positive tumors.
Knebel N; Schiller CD; Schneider MR; Schönenberger H; von Angerer E
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):293-9. PubMed ID: 2702983
[TBL] [Abstract][Full Text] [Related]
4. 3-Alkyl-2-phenylbenzo[b]thiophenes: nonsteroidal estrogen antagonists with mammary tumor inhibiting activity.
von Angerer E; Erber S
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):557-62. PubMed ID: 1562527
[TBL] [Abstract][Full Text] [Related]
5. Platinum complexes with binding affinity for the estrogen receptor.
Knebel N; von Angerer E
J Med Chem; 1988 Sep; 31(9):1675-9. PubMed ID: 3411596
[TBL] [Abstract][Full Text] [Related]
6. 6-Alkyl-12-formylindolo[2,1-a]isoquinolines. Syntheses, estrogen receptor binding affinities, and stereospecific cytostatic activity.
Polossek T; Ambros R; von Angerer S; Brandl G; Mannschreck A; von Angerer E
J Med Chem; 1992 Sep; 35(19):3537-47. PubMed ID: 1404234
[TBL] [Abstract][Full Text] [Related]
7. Structure activity studies on leaving group derivatives of [meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] platinum(II).
Gust R; Keilitz R; Krauser R; Schmidt K; Schnurr B
Arch Pharm (Weinheim); 1999 Aug; 332(8):261-70. PubMed ID: 10489536
[TBL] [Abstract][Full Text] [Related]
8. 2-Phenylbenzo[b]furans: relationship between structure, estrogen receptor affinity and cytostatic activity against mammary tumor cells.
Erber S; Ringshandl R; von Angerer E
Anticancer Drug Des; 1991 Nov; 6(5):417-26. PubMed ID: 1764164
[TBL] [Abstract][Full Text] [Related]
9. 2-Phenylindoles. Effect of N-benzylation on estrogen receptor affinity, estrogenic properties, and mammary tumor inhibiting activity.
von Angerer E; Strohmeier J
J Med Chem; 1987 Jan; 30(1):131-6. PubMed ID: 3806590
[TBL] [Abstract][Full Text] [Related]
10. Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.
Karl J; Gust R; Spruss T; Schneider MR; Schönenberger H; Engel J; Wrobel KH; Lux F; Haeberlin ST
J Med Chem; 1988 Jan; 31(1):72-83. PubMed ID: 3336035
[TBL] [Abstract][Full Text] [Related]
11. Dibenzo[a,g]quinolizin-8-ones: synthesis, estrogen receptor affinities, and cytostatic activity.
von Angerer S; Brandl G; Mannschreck A; Weimar C; Wiegrebe W
Anticancer Drug Des; 1992 Oct; 7(5):351-63. PubMed ID: 1388628
[TBL] [Abstract][Full Text] [Related]
12. Benzo[a]carbazole derivatives. Synthesis, estrogen receptor binding affinities, and mammary tumor inhibiting activity.
von Angerer E; Prekajac J
J Med Chem; 1986 Mar; 29(3):380-6. PubMed ID: 3950918
[TBL] [Abstract][Full Text] [Related]
13. 2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
von Angerer E; Prekajac J; Strohmeier J
J Med Chem; 1984 Nov; 27(11):1439-47. PubMed ID: 6492074
[TBL] [Abstract][Full Text] [Related]
14. Dibenzo[a,f]quinolizines: syntheses and cytostatic activity in estrogen-sensitive tumor cells.
von Angerer S; Seidl E; Mannschreck A; von Angerer E; Wiegrebe W
Anticancer Drug Des; 1994 Feb; 9(1):25-40. PubMed ID: 8141964
[TBL] [Abstract][Full Text] [Related]
15. Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II) by variation of ring substituents.
Gust R; Karl J; Faderl M; Schönenberger H
Arch Pharm (Weinheim); 1995 May; 328(5):457-63. PubMed ID: 7611841
[TBL] [Abstract][Full Text] [Related]
16. [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
Gust R; Faderl M; Schönenberger H
J Cancer Res Clin Oncol; 2000 Nov; 126(11):647-54. PubMed ID: 11079729
[TBL] [Abstract][Full Text] [Related]
17. 2-phenylindole-linked nitroimidazoles as potential radiosensitizers for estrogen receptor positive tumors.
Erber S; von Angerer E
Arch Pharm (Weinheim); 1990 Sep; 323(9):591-4. PubMed ID: 2288481
[TBL] [Abstract][Full Text] [Related]
18. Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
Schertl S; Gust R; Müller R; Spruss T; Schönenberger H
Arch Pharm (Weinheim); 1992 Feb; 325(2):113-8. PubMed ID: 1605715
[TBL] [Abstract][Full Text] [Related]
19. 2-Phenylindoles with sulfur containing side chains. Estrogen receptor affinity, antiestrogenic potency, and antitumor activity.
Biberger C; von Angerer E
J Steroid Biochem Mol Biol; 1996 Apr; 58(1):31-43. PubMed ID: 8809184
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic esters of 1,1-bis-(4-hydroxyphenyl)-2-phenyl-but-1-ene with selective antitumor activity against estrogen receptor-containing mammary tumors.
Schuderer ML; Schneider MR
J Cancer Res Clin Oncol; 1987; 113(3):230-4. PubMed ID: 3584214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
